Participant flow

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin · Source last updated 2016-07-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   All patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase. Patients included patients with pancreatic neuroendocrine tumors (PNETs), pituitary NETs (PiNETs), Ectopic ACTH-secreting tumor (EAS) \& Nelson's syndrome.

   id

   FG000

   title

   Pasireotide LAR 60mg

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Abnormal laboratory value(s)

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Abnormal test procedure result(s)

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Administrative problems

   4. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Adverse Event

   5. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      New cancer therapy

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   7. reasons

      1. group Id

         FG000

         num Subjects

         22

      type

      Unsatisfactory therapeutic effect

   8. reasons

      1. group Id

         FG000

         num Subjects

         27

      type

      Completed M6/did not enter extension

   9. reasons

      1. group Id

         FG000

         num Subjects

         28

      type

      Discontinued prior to M*

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         118

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         90

      type

      Completed Month 6 (M6)

   3. achievements

      1. group Id

         FG000

         num Subjects

         63

      type

      Entered in Extension

   4. achievements

      1. comment

         Completed = Completed extension

         group Id

         FG000

         num Subjects

         22

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         96

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

For all other individual indications, the numbers of patients in the efficacy analyzable sets were less than 6 and therefore no responder analyses were carried out for these indications.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice